BiotechTube
Cellastra

Cellastra

San Francisco, United States· Est.
cellastra.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cellastra is an early-stage biotech focused on a significant unmet need: preventing pathological scarring and fibrosis. The company's core technology involves using AAV vectors to deliver the gene for Ensereptide, an anti-scarring peptide, directly to injury sites to promote scar-free healing. Led by a seasoned team with deep drug development and regulatory experience, Cellastra is currently seeking investors and development partners to advance its pipeline. Its initial targets include pulmonary fibrosis, burn injuries, and post-surgical adhesions.

Pulmonary FibrosisBurn InjuriesSurgical AdhesionsTraumatic Brain Injury

Technology Platform

Proprietary AAV vector technology designed to deliver the gene for Ensereptide, a natural derivative of Lactoferrin with anti-scarring properties, to target cells at sites of injury to promote scar-free healing.

Opportunities

The global market for anti-fibrotic and anti-scarring therapies is vast and underserved, spanning pulmonary diseases, surgical complications, and burn care.
A successful, one-time, preventive gene therapy could command premium pricing and capture significant value across multiple multi-billion dollar indications.
The experienced leadership team improves the odds of navigating the complex development and regulatory pathway.

Risk Factors

The core scientific premise of preventing scarring via AAV-delivered Ensereptide is unproven and faces high technical and biological risk.
As a preclinical, pre-revenue company, it is entirely dependent on securing external funding.
It will also face significant regulatory hurdles inherent to novel gene therapies and competition from other modalities targeting fibrosis.

Competitive Landscape

The anti-fibrotic space is competitive, with large pharma (e.g., Boehringer Ingelheim, Roche) marketing drugs for IPF and many biotechs exploring novel targets. Cellastra's primary differentiation is its gene therapy approach aimed at prevention rather than slowing progression. It may face competition from other regenerative approaches, including stem cell therapies and other gene-editing or RNA-based platforms.

More companies in Cell & Gene Therapy →More companies in United States →